We need to have a good idea soon. A few trials are now being tested to test the effectiveness of the vaccine, the results of which began earlier this month. If these hybrids are safe and effective, countries will be able to roll out the vaccine even if another vaccine is delayed due to delays, unexpected shortages, or security concerns.
But there is another exciting prospect that could be an important part of our path in the future: mixing vaccines can bring complete protection and prevent the virus that is being tested to protect our immune system. In the end, mixed-use methods can be the best protection.
Mix in case
The covid-19 vaccine used here protects against viruses in a variety of ways. Many fight against the coronavirus protein, which it uses to invade our cells. But others offer instructions for the production of proteins in the form of messenger RNA (Pfizer, Moderna). Some produce the same protein (Novavax). Some use a harmless virus to climb on its instructions, such as the Trojan horse (Johnson & Johnson, Oxford-AstraZeneca, Sputnik V). Some offer unstable viruses (Sinopharm, Sinovac).
Mu research published in March, researchers from China’s National Institutes for Food and Drug Control tested a variety of covid-19 vaccines in mice, and found that some had improved immunity. As soon as he started giving rats a vaccine that relied on a harmless cold virus to smuggle in instructions and then a second dose of another vaccine, he noticed high levels of antibody and normal T-cell responses. But after changing the law, and giving the virus vaccine a second time, they saw no change.
Because the combination of shots can help make the work more effective and confidential, says Shan Lu, a medical and vaccine researcher at the University of Massachusetts Medical School who developed the technique. “We can explain a little bit, but we don’t really understand it.” Different vaccines provide different matching information. These differences can trigger different levels of the immune system or increase the immune system. This approach may also result in temporary security.
It is unknown at this time what he will do after leaving the post. Researchers at Oxford University have set up human trials to test how the mixture can work. The study, called Com-CoV, gives students the first shot of Pfizer or Oxford-AstraZeneca. At their second dose, they will also take the same vaccine or shoot Moderna or Novavax. Preliminary results should be available in the coming weeks.
Other studies are also being conducted. In Spain, where Oxford-AstraZeneca is now distributed to more than 60 people, researchers are planning to enroll 600 people to test whether the first shot level could be combined with the second level from Pfizer. According to reports in El País, nearly a million people received the first vaccine but were unable to receive the second vaccine. Health officials are awaiting the results of the study before commenting on the team, but it is not known if the students are still enrolled.
Late last year Oxford-AstraZeneca announced that it was partnering with the Russian Gamaleya Institute, which developed the Sputnik V vaccine, to test the effectiveness of all these shots. The trial is set to begin in March and will take place later in May, but it is unknown at this time what he will do after leaving the post. And Chinese officials have said they have developed a mixed vaccine to help their shooting.
Significant benefits can come from mixing vaccines with low potency. The mRNA vaccine from Pfizer and Moderna is very protective. “I don’t think there’s any reason to confuse this,” says Donna Farber, a clinical psychologist at Columbia University. But the combination could protect the safety of other vaccines that have claimed less protection, such as Oxford-AstraZeneca and Johnson & Johnson, as well as other Chinese vaccines. Most vaccines work well, but mixing them can help them work better.